Cite
HARVARD Citation
Soubrier, M. et al. (n.d.). AB0696 Retention rates of adalimumab, etanercept, and infliximab as first- or second-line biotherapies for spondyloarthritis patients in daily practice in auvergne (france). Annals of the rheumatic diseases. p. 1297. [Online].